A new study showed that Merck & Co, Inc., a national pharmaceutical manufacturing company, knew that its anti-cholesterol drug, Vytorin, was no more effective than generic counterparts--which cost much less.
Unfortunately, Merck falsely represented to its customers that Vytorin was more effective than the less expensive drugs.
Health care costs are already too high for most average Americans. This study reveals that consumers needlessly overpaid for name-brand drugs when the generic, less expensive alternatives would have been just as effective.
In related news, Merck reported $24.31 million in revenue for 2007.
No comments:
Post a Comment